tbuckley/cabot-search huggingface dataset:
Vers une prophylaxie post-exposition au VIH chez les personnels de santé en Europe
Authors: V Puro, S Cicalini, G De Carli, F Soldani, G Ippolito
Journal: Eurosurveillance (2004)

La prophylaxie post-exposition au VIH (PEP) chez les personnels de sante est utilisee dans toute l'Europe, sans qu'il y ait pour autant d'approche homogene. Un groupe d'experts, finance par la Commission europeenne, a emis des recommandations. 
Des lors qu'il a ete etabli que les caracteristiques de l'exposition determinent l'initiation d'une PEP, le traitement doit debuter le plus rapidement possible ; au dela de 72 heures apres l'exposition, la PEP n'est cependant pas recommandee. Le traitement devrait debuter en routine avec une combinaison de trois antiretroviraux approuves dans le traitement des patients infectes par le VIH ; avec une preference pour une prescription de deux classes differentes d'antiretroviraux. Les traitements anterieurs devraient etre recherches chez le patient source. Un depistage du VIH et une evaluation clinique, accompagnes de conseils et d'un soutien psychologique, devraient etre menes tout de suite apres l'exposition, puis apres un delai de 6 a 8 semaines, et enfin, au moins six mois apres. Des controles cliniques et microbiologiques supplementaires devraient etre envisages une a deux semaines apres l'exposition, l'adhesion et la tolerance au traitement pouvant reveler des effets secondaires et une potentielle toxicite. Ni les tests en routine de resistance aux antiretroviraux chez le patient source, ni la recherche directe du virus chez les personnels soignants exposes ne sont recommandes.
Srage as biomarker for COPD, introducing novel LC-MS-based methods for the quantification of serum srage levels
Authors: S.D. Pouwels, F. Klont, N. Van De Merbel, P. Horvatovich, N.H.T. Ten Hacken, R. Bischoff
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Rationale: Soluble RAGE (sRAGE) is a promising biomarker for COPD and an attractive target for biomarker validation studies. Validated, reliable and clinically applicable biomarkers are needed for the early detection of COPD, identification of clinically relevant subgroups of COPD and for the selection of subjects for clinical trials. The circulating levels of sRAGE are decreased in COPD patients compared to both smoking and non-smoking controls, and are even further decreased during COPD exacerbations. Furthermore, the serum levels of sRAGE associate with neutrophilic airway inflammation, decline in FEV1, and emphysema. Methods: To date, most studies use commercially available ELISA kits for measurements of sRAGE, which have limited accuracy and reproducibility. Here, we present two novel liquid chromatography-mass spectrometry (LC-MS) methods for the quantification of sRAGE in serum. Our first approach measures the free, unbound fraction of sRAGE using an immunoaffinity enrichment-based method as sample preparation, comparable to the ELISA. Our second approach is an antibody-free method based on strong cation exchange solid-phase extraction, which likely measures the total sRAGE fraction. Both sample preparation methods are followed by LC-MS analysis in the multiple reaction monitoring mode. Results: Using the immunoaffinity enrichment-based method we are able to detect and quantify sRAGE in human serum over a large range (0.1-10 ng/mL) with high precision and accuracy (CV
Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly-diagnosed glioblastoma
Authors: M. Fontanilles, F. Clatot, C. Alexandru, O. Langlois, O. Veresezan, F. Marguet, M. David, A. Laquerriere, C. Hanzen, I. Tennevet Bouilly, F. Di Fiore
Journal: Annals of Oncology (2017)
The European Centre for Disease Prevention and Control launches a public consultation. Send your comments!
Authors: A Kanellopoulou, A Jansen
Journal: Eurosurveillance (2012)

Preview this article: The European Centre for Disease Prevention and Control launches a public consultation. Send your comments!, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/17/28/art20219-en-1.gif
Inflammation and cardio‐renal interactions in heart failure: a potential role for interleukin‐6
Authors: Jennifer S. Hanberg, Veena S. Rao, Tariq Ahmad, Zobia Chunara, Devin Mahoney, Keyanna Jackson, Daniel Jacoby, Michael Chen, F. Perry Wilson, W.H. Wilson Tang, Rahul Kakkar, Jeffrey M. Testani
Journal: European Journal of Heart Failure (2017)
Quantitative multimarker analysis in circulating tumor cells of patients with breast cancer
Authors: N. Fersis, D. Koliogiannis, L. Sisic, B. Schlehe, M. J. Battista, C. Sohn, S. Kaul
Journal: Journal of Clinical Oncology (2007)

1021 Background: The purpose of this study was clinical application of new methods for quantitative gene expression analysis of circulating tumor cells (CTC) in breast cancer patients. Methods: The high affinity antibodies BM7 (MUC-1) and VU1D9 (EpCAM) were used for immunomagnetic tumor cell enrichment in 10 mL of peripheral EDTA-blood of patients with primary breast cancer (n=167) and metastatic disease (n=131). Separated cells were lysed and used for mRNA isolation and c-DNA synthesis. The breast carcinoma- associated markers MUC1 and EpCAM were determined by conventional RT-PCR. The markers cytokeratin 19 (CK19), mammaglobin 1, survivin, HER-2, CXCR4 and prostate-specific ets factor (PSE) were amplified by real-time quantitative RT-PCR using primers and FAM-labeled TaqMan probes selected with the UniversalProbeLibrary system (Roche AG, Basel, CH). The β-actin transcript served as internal process quality control. Specificity of the RT-PCR was confirmed by examination of blood of healthy donors. Results: Sensitivity for every single transcript was adjusted to 2 tumor cells per 5 ml blood. Tumor-associated transcripts were detected in 31 of 167 (18.5%) patients with primary breast cancer. The marker with the highest incidence of 81% was MUC1. Patients with metastatic disease (n=131) had a positivity rate of 56% and were characterized by multiple marker expression. During a 12 (9–15) months follow-up of 81 patients with primary breast cancer, multimarker positivity was determined in 10 patients, and in three of these patients early metastasis was clinically confirmed. In patients with metastatic disease the CK19 positive CTCs co-expressed either survivin, PSE, CXCR4 or HER2 in more than 70% of the cases. Conclusion: Using a combination of preanalytical immunomagnetic tumor cell enrichment, followed by a multigene quantitative RT- PCR approach, we describe a sensitive detection system for rare circulating breast carcinoma cells. By quantitative expression analysis, survivin, PSE, CXCR4 and HER2 together with CK19 were identified as reliable markers for early detection of metastasis and for prediction of risk of recurrence. The marker panel can be extended further to match patients to best drugs and to predict treatment benefits. No significant financial relationships to disclose.
L’incidence de la bactériémie à S. aureus dans les hôpitaux de soins de la zone Centre-Ouest en Irlande, 2002-2004
Authors: D Whyte, R Monahan, L Boyle, B Slevin, R FitzGerald, D Barron, J De Freitas, K Kelleher
Journal: Eurosurveillance (2005)

L’inquietude face aux infections nosocomiales, et le phenomene mondial de resistance aux antibiotiques, ont renforce les craintes de ce que les anglophones appellent un « superbug ». En Irlande, il n’existe pas d’indicateur considere comme une mesure fiable du niveau de Staphylococcus aureus resistants a la methicilline (SARM) dans les hopitaux. L’objectif de l’etude presentee ici etait de comparer deux mesures brutes des SARM – le pourcentage de bacteriemies dues aux SARM et le taux d’incidence (par 1000 lits occupes/jour) des SARM dans six hopitaux. Nous avons analyse tous les prelevements sanguins positifs pour S. aureus (qu’ils soient sensibles ou resistants a la methicilline) de 2002 a 2004, dans la region Centre-Ouest de l’Irlande. Les donnees des dossiers medicaux (Hospital In-Patient Enquiry, HIPE) ont servi a determiner pour chaque mois le taux d’occupation des lits. 
Sur les 245 episodes de bacteriemie de patients, 119 etaient des SARM. Les tendances des pourcentages d’isolats de SARM ont ete compares aux taux d’incidence calcules. Le taux d’incidence semble etre un indicateur de SARM dans les hopitaux plus fiable et solide que le pourcentage. Les difficultes d’interpretation des indicateurs de SARM ne devraient pas empecher la publication reguliere de donnees, au moins a l’echelon regional, en Irlande.
Combination of anti-PD-1/PD-L1 antibodies with chemotherapy or CTL4 antibodies for first-line treatment of advanced lung cancer.
Authors: Yun Fan, Xiaoling Xu
Journal: Journal of Clinical Oncology (2017)

e20538 Background: Checkpoint inhibitors showed satisfactory efficacy in treating lung cancer. We conducted this meta-analysis to explore the therapeutic efficacy and safety of anti-PD-1/PD-L1 antibodies combine with chemotherapy or CTL4 antibodies as first-line treatment on advanced lung cancer. Methods: A quantitative meta-analysis was performed through a systematic search in PubMed, Web of Science, the conference abstracts and so on. The pooled ORR, 6-month progression-free survival rate (PFSR 6m ), and 1-year overall survival rate (OSR 1y ) were calculated and compared. 9 trials were included in this meta-analysis. Results: Our analyses demonstrated the pooled ORR and DCR of anti-PD-1/PD-L1 antibodies combine with chemotherapy for non-small-cell lung cancer were 48.0% (40.2–56.0 %) and 84.8 % (78.1– 89.7%), respectively. The pooled OR and DCR of anti-PD-1/PD-L1 antibodies combine with chemotherapy for small-cell lung cancer were 42.9% (18.5–71.2 %) and 73.6 % (32.8–94.1%), respectively. The pooled PFSR 6m of anti-PD-1/PD-L1 antibodies combine with chemotherapy for NSCLC and SCLC were 62.9% (46.3–79.6%) and 27.6 % (18.9–36.2 %), respectively. The OSR 1y of anti-PD-1/PD-L1 antibodies combine with chemotherapy for NSCLC and SCLC were 70.1 % (57.4%-82.8 %) and 32.0 % (25.2–38.9 %). In addition, the pooled ORR and DCR for anti-PD-1/PD-L1 antibodies plus CTL4 antibodies treatment group was 29.6% (11.4%-657.8%) and 48.7% (16.8%-81.7%), respectively. Conclusions: Anti-PD-1/PD-L1 antibody plus chemotherapy can serve as a promising treatment option for lung cancer. While patients treated anti-PD-1/PD-L1 antibodies plus CTL4 antibodies may benefit less compare with anti-PD-1/PD-L1 antibodies combine with chemotherapy. Encouraging activity with tolerable adverse effect was observed.
GW28-e0465 NEUTROPHIL-TO-LYMPHOCYTE RATIO AND MONOCYTE COUNT IN PATIENTS WITH CARDIOGENIC SHOCK, DEPENDING ON THE SEVERITY OF CORONARY ARTERY LESIONS
Authors: Galina Kukharchik, Olga Lebedeva, Gleb Saraev, Lev Sorokin
Journal: Journal of the American College of Cardiology (2017)
Impact of preprocedure simethicone on adenoma detection rate during colonoscopy: a multicenter, endoscopist-blinded randomized controlled trial
Authors: Yu Bai, Jun Fang, Sheng-Bing Zhao, Dong Wang, Yan-Qing Li, Rui-Hua Shi, Zi-Qin Sun, Ming-Jun Sun, Feng Ji, Jian-Min Si, Zhao-Shen Li
Journal: Endoscopy (2017)

Abstract Background and study aims Ideal bowel preparation for colonoscopy requires complete removal of fluid and foam from the colon. Polyethylene glycol (PEG) is widely used for bowel preparation, with antifoaming agents such as simethicone commonly used in combination with PEG. Data on the effect of simethicone on the adenoma detection rate (ADR) were limited. This study therefore aimed to investigate whether preprocedure simethicone could increase the ADR. Patients and methods This was a prospective, multicenter, endoscopist-blinded randomized controlled trial involving consecutive patients who underwent colonoscopy in six centers in China. Patients were randomly assigned to one of two groups: PEG plus simethicone or PEG alone. The primary outcome was ADR; secondary outcomes were quality of bowel preparation, measured by the Boston bowel preparation scale (BBPS) and bubble scores. Results 583 patients were included. More adenomas were detected in the PEG plus simethicone group than in the PEG alone group (ADR 21.0 % vs. 14.3 %, P = 0.04; advanced ADR 9.0 % vs. 7.0 %, P = 0.38). The mean number of adenomas detected was 2.20 ± 1.36 vs. 1.63 ± 0.89 (P = 0.02). Patients in the PEG plus simethicone group showed better bowel cleansing efficacy: BBPS ≥ 6 in 88.3 % vs. 75.2 % (P &lt; 0.001) and bubble scores of 1.00 ± 1.26 vs. 3.98 ± 2.50 (P &lt; 0.001). Abdominal bloating was reported less frequently in the PEG plus simethicone group (7.8 % vs. 19.7 %, P &lt; 0.001) than in the PEG alone group. Conclusion Combined use of PEG and simethicone is associated with a significantly increased ADR in a Chinese population. Clinical trials registration number: NCT02540239
Tumor Treating Fields (TTFields) – A novel cancer treatment modality: Translating preclinical evidence and engineering into a survival benefit with delayed decline in quality of life
Authors: R. Stupp, M. Taphoorn, L. Dirven, S. Taillibert, J. Honnorat, T. Chen, J. Sroubek, S.H. Paek, J. Bruna Escuder, J. Easaw, C. David, C.Y. Kim, R. Desai, Y. Kew, A. Olivi, A. Hottinger, E.D. Kirson, G. Lavy-Shahaf, M.E. Hegi, Z. Ram
Journal: Annals of Oncology (2017)
Late Adherent Subpopulation in Umbilical Cord Blood Has the Same Characteristics and Hematopoiesis-Supporting Capacity As Mesenchymal Stromal/Stem Cells
Authors: Satoshi Yoshioka, Yasuo Miura, Masaki Iwasa, Aya Fujishiro, Noriko Sugino, Sumie Fujii, Yoko Nakagawa, Atsushi Sato, Asumi Yokota, Hideyo Hirai, Tatsuo Ichinohe, Akifumi Kondo Takaori, Taira Maekawa
Journal: Blood (2016)
Understanding BRCA1 and BRCA2 mutated breast cancer cases in Romania: First report on founder mutations in Romanians
Authors: A. Eniu, L. Pop, A. Stoian, E. Dronca, R. Matei, M. Ligtenberg, H. Ouchene, A. Onisim, O. Rotaru, R. Eniu, N. Antone
Journal: Annals of Oncology (2017)
Identification of genomic features underlying response of muscle-invasive bladder cancer (MIBC) to neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) in an open-label, single-arm, phase 2 study
Authors: D. Raggi, A. Paoli, M. Dugo, P. Giannatempo, L. De Cecco, M. Colecchia, M.G. Daidone, A. Necchi, M.L. Sensi
Journal: Annals of Oncology (2017)
Abstract 15992: Ventricular Tachyarrhythmia Sensing Following Magnetic Resonance Imaging in Patients With an ICD System Designed for the MRI Environment
Authors: Michael R Gold, Torsten Sommer, Juerg Schwitter, Emanuel Kanal, Matthew Bernabei, Charles Love, Ralf Surber, Brian Ramza, Jeffrey Cerkvenik, Béla Merkely
Journal: Circulation (2015)

Objective: To evaluate the impact of MRI on ICD sensing of ventricular tachyarrhythmias. Methods: The Evera MRI study is the first randomized trial of an ICD designed specifically to be MRI safe. This was a world-wide trial of 263 pts implanted with an Evera MRI single or dual chamber ICD in 42 centers. Patients were randomized to either undergo an MRI scan (MRI group) or to not receive a study MRI scan. Per protocol, 156 MRI group pts underwent an MRI procedure at 9-12 weeks post-implant. Device detected spontaneous and induced VT/VF episodes in the MRI group occurring prior to and following MRI were evaluated by an independent Episode Review Committee blinded to the timing of events. Detection delay was computed as the sum of RR intervals of under sensed beats. A ≥5 second delay in detection due to under sensing was prospectively defined as clinically significant. P-values are adjusted for multiple episodes within a patient. Results: There were a total of 34 post-MRI VT/VF episodes in 24 pts, with 16 of those pts having 27 VT/VF episodes prior to MRI. The mean detection delay due to under sensing in the 23 pre-MRI treated episodes was 0.37 ± 0.57 seconds, compared to 0.25 ± 0.57 in 27 treated post-MRI episodes (p=0.29). The maximum detection delay was 2.19 seconds pre-MRI and 2.87 seconds post-MRI. Monomorphic VT and non-sustained VT/VF rarely had any under sensing with 1/11 (9%) pre-MRI episodes and 1/14 (7%) post-MRI episodes (p=0.81) having 2 and 1 under sensed beats, respectively. For polymorphic VT/VF episodes, 13/16 (81%) pre-MRI episodes had some detection delay vs. 10/20 (50%) in post-MRI episodes (p=0.052), but no detection delay was clinically significant. The duration of delay was 0.54 ± 0.61 vs 0.32 ± 0.64, respectively, p=0.28). Conclusion: Detection of VT/VF was excellent with no significant impact of MRI with this system.
APOL1 nephropathy risk variants do not associate with subclinical atherosclerosis or left ventricular mass in middle-aged black adults
Authors: Orlando M. Gutiérrez, Sophie Limou, Feng Lin, Carmen A. Peralta, Holly J. Kramer, J. Jeffrey Carr, Kirsten Bibbins-Domingo, Cheryl A. Winkler, Cora E. Lewis, Jeffrey B. Kopp
Journal: Kidney International (2017)
Legionelosis asociada a los viajes en Europa, en 2000 y 2001
Authors: C A Joseph
Journal: Eurosurveillance (2003)

El Programa Europeo de Vigilancia de Legionelosis Asociada a los Viajes (European Surveillance Scheme for Travel Associated Legionnaires' Disease; EWGLINET) recibio notificacion de 360 casos en 2000 y 481 casos en 2001, la cifra mas elevada declarada desde 1987. Este aumento refleja una mejora en las actividades de vigilancia, especialmente en Paises Bajos, Francia e Italia, principalmente a traves de la prueba de deteccion del antigeno urinario (78% de los casos en 2001). La mediana de retraso en el envio de declaraciones al programa se redujo a menos de treinta dias, a expensas de cierta perdida de informacion de los resultados de la enfermedad. En 2000, se detectaron 28 agrupaciones o clusters, frente a las 72 de 2001, debiendose este aumento sobre todo a un cambio en la definicion de las agrupaciones. En 2000 y 2001, se notificaron 55 y 140 investigaciones ambientales respectivamente.
Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI- GOIM trial
Authors: F. Ciardiello, E. Martinelli, C. Cardone, T. Troiani, N. Normanno, S. Pisconti, R. Bordonaro, A. Nappi, F. Giuliani, M. Biglietto, C. Barone, A.M. Rachiglio, V. Montesarchio, S. Cinieri, D. Rizzi, A. Febbraro, T. Latiano, G. Modoni, G. Colucci, E. Maiello
Journal: Annals of Oncology (2017)
Inhibition of primary rhabdoid tumors arising in Ini1+/- knock-out mice by a Cyclin/cdk inhibitor
Authors: Velasco Cimica, Melissa Smith, Srinivasa Chinni, Suman Jana, Sridhar Mani, Ganjam Kalpana
Journal: Cancer Research (2007)

508   Introduction: Rhabdoid tumors (RT) are rare, aggressive and currently incurable pediatric malignancies. INI1/hSNF5, a component of the SWI/SNF complex, is a critical tumor suppressor biallelically inactivated in these tumors. Mice heterozygous for Ini1 develop a high frequency of tumors with etiology and characteristics similar to human RTs and hence are excellent models for developing novel therapeutic strategies. INI1 causes G0-G1 arrest of rhabdoid cells by repressing Cyclin D1 (Zhang 2002 MCB:22-5975) and activating p16INK4a and p21CIP. RTs are exquisitely dependent on Cyclin D1 in vitro and in vivo (Tsikitis 2005 PNAS:102-12129). Therapeutic down-modulation of Cyclin D1 correlated to the inhibition of RT xenografts, indicating that targeting Cyclin/cdk is a potential novel therapeutic strategy for RTs (Alarcon-Vargas 2006 Oncogene:25-722). However, primary RT models have not been used in preclinical testing and Cyclin dependent kinase (cdk) inhibitors have never been tested in preclinical or clinical studies of RTs, to date.  Method: Here we have tested the effect of Flavopiridol, a pan-cdk inhibitor, in vitro, and analyzed its effect on rhabdoid cell survival and induction of cell cycle arrest and apoptosis. Furthermore, we have tested the therapeutic efficacy of Flavopiridol in RT xenografts and in primary mouse RTs arising in Ini1+/- knock-out mice, by combining the power of a non-invasive imaging modality, the microPET (positron emission tomography).  Results: We found that rhabdoid cells are sensitive to low concentration of Flavopiridol (IC50 ~200 nM). Flavopiridol induced G1 arrest, down modulated Cyclin D1, up-regulated p21 and induced dose- and time-dependent increase in apoptosis that was correlated to induction of caspase 3/7 activity in rhabdoid cells. Treatment of mice harboring RT xenografts with clinically achievable concentrations of 7.5 mg/kg/day Flavopiridol, five times a week, for two weeks, effectively inhibited the growth of RT xenografts (p  Conclusions: Flavopiridol induces cell cycle arrest and apoptosis and inhibits growth of xenografts and primary RTs in vivo. Our studies indicate that microPET imaging is a powerful means of studying primary mouse RTs and that targeting cyclin/cdk is an effective means of inhibiting RTs in vivo. Flavopiridol is a novel chemotherapeutic agent for RTs.
Is there receptor tyrosine kinases expression on lymphocytes in patients with renal cell carcinoma? First-in-human study
Authors: D. Khochenkov, M. Volkova, A. Olshanskaia, S. Aschuba, Y. Khochenkova, A. Anastasia Bondarenko, I. Tsimafeyeu
Journal: Annals of Oncology (2017)
GW28-e1214 Ablation of idiopathic frequent ventricular premature contraction with non-X-ray fluoroscopic or routine X-ray fluoroscopic ablation catheter: results on health-related quality of life
Authors: Deng Xiaojiang, Zhu Tingyan, Chen Yizhen, He Liwei, Chen Yanyu, Liu Shenrong, Xie Liangzhen, He Zhihui, Kang Ying, Peng Jian
Journal: Journal of the American College of Cardiology (2017)
Evaluation of indoleamine 2,3-dioxygenase expression (IDO), transforming growth factor beta (TGF-β) and interleukin 13 (IL13) expression on clinical outcome in patients with Hodgkin’s lymphoma
Authors: T. Skrypets, O. Novosad, Y. Pastushenko, O. Skachkova, O. Gorbach, N. Khranovska, I. Kryachok
Journal: Annals of Oncology (2017)